Epazz, Inc. Reports Increase First Quarter Revenue and Profitability; Company is Focusing on Improving Fundamentals; Increasing Sales, Reducing Operational Expenses and Increasing Income

Epazz, Inc. Reports Increase First Quarter Revenue and Profitability; Company is Focusing on Improving Fundamentals; Increasing Sales, Reducing Operational Expenses and Increasing Income

CHICAGO, IL — (Marketwired) — 05/23/17 — . (OTC PINK: EPAZ), a leading provider of cloud-based business software solutions, has announced that the Company has reported its first quarter results for 2017. The Company reported revenue of $473,974 (unaudited) compared to $416,260 for the first quarter 2016. The Company reported a net income of $28,186 (unaudited) compared to a loss of $375,553 for the first quarter of 2016. This is a substantial turnaround in the Company–s financial position.

Life Sciences and Medical Research Turn to Qumulo for Modern Scale-Out File Storage

Life Sciences and Medical Research Turn to Qumulo for Modern Scale-Out File Storage

Johns Hopkins Genomics at The Johns Hopkins University, Georgia Cancer Center at Augusta University, CID Research, Progenity, Inc., DarwinHealth, Inc., and Channing Division of Network Medicine at Brigham and Women–s Hospital Among New Qumulo Customers; Qumulo Reports More Than 2X Growth in Petabytes Shipped to Life Sciences and Medical Research Customers in 12 Months

GPS SmartSole Used in Wandering Prediction Trial George Mason University–s College of Health and Human Services Completes Phase One of Wandering Predication Research

GPS SmartSole Used in Wandering Prediction Trial George Mason University–s College of Health and Human Services Completes Phase One of Wandering Predication Research

LOS ANGELES, CA — (Marketwired) — 05/23/17 — (OTC PINK: GTXO), an IoT platform in the personal location wearable and wandering assistive technology business, announced today that George Mason University–s College of Health and Human Services has successfully completed phase one of the wandering prediction trial which began in . In collaboration with investigators from the Milken Institute School of Public Health at George Washington University, who have expertise in the economics of patien

Lexington Biosciences Introduces President and Board Chair

Lexington Biosciences Introduces President and Board Chair

VANCOUVER, BC — (Marketwired) — 05/23/17 — (CSE: LNB) (LNB.CN) (CNSX: LNB) (the "Company" or "Lexington"), a development-stage medical device company operating within the healthcare industry, is pleased to introduce and welcome Mr. Eric Willis as Company President, and Mr. Doug Janzen as Board Chairman.Mr. Willis is a twenty plus year veteran of the healthcare technology industry with a passion for working closely with clinicians to bring products from concept to market.